The Diurnal Board combines many years of business acumen, first-hand intellectual property experience and financial expertise to support the company.

Kevin Bryett, MB BS MFPM – Non-Executive Chairman

Kevin Bryett originally qualified as a physician at St George’s Medical School London, and worked in both hospital and general practice before entering the pharmaceutical industry in 1982. Subsequently, he has held a number of senior management positions in the global vaccines industry, including Managing Director of companies in the UK and Germany, and Vice President of European Commercial Operations for Aventis (now Sanofi) Pasteur MSD. More recently he held the position of Vice President of Global Commercial Operations for the world’s fifth largest vaccines business, Chiron Vaccines. In this role he was a core member of the team that managed the $1 billion acquisition of the world’s sixth largest vaccines company, PowderJect Pharmaceuticals. As a senior industry executive, Dr Bryett has sat on several strategic and operational Boards both globally and in a number of European countries. He now divides his time between running his own management consultancy and acting as a non-executive director in the biotechnology sector.

Richard Ross, MD FRCP - Chief Scientific Officer

Richard Ross is a founding director of the Diurnal. Richard is a clinical Endocrinologist in the Department of Human Metabolism, University of Sheffield and was previously a Senior Lecturer at St. Bartholomew's Hospital, London. Richard’s primary research interest is pituitary disease with a particular focus on hormone replacement. He has been a member of the editorial boards of four international endocrine journals, and served as an elected member of council for the Society for Endocrinology. He has extensive experience in both investigator led and pharmaceutically driven clinical trials. Richard has acted as a consultant for most of the big pharmaceutical companies active in the endocrine field including: Pharmacia, Novo Nordisk, Eli Lilly, Serono, Ferring and Ipsen and is currently a member of a Lilly International Advisory Board. Richard has published over a 100 peer-reviewed articles including recent publications in Nature Medicine, Nature Genetics, The Lancet, and PNAS.

Peter Grant, PhD - Non Executive Director

Peter Grant is a founder director of Fusion IP PLC, an AIM listed company involved in commercialising university-based research. Peter is also a non-executive director of Adjuvantix Limited and Asterion Limited, all companies acting in the field of human healthcare. Following his PhD, Peter joined Genzyme UK as a Senior Research Scientist working within the clinical diagnostics division. He moved to Celltech from Genzyme, and was then recruited by Sir Christopher Evans to join the start-up team at Enzymatix Limited where he became the Head of R&D, spanning five business areas. Two of these were later spun out to form Chiros (later Chiroscience) and Celsis with Peter as a co-founder and R&D Director. Following venture capital funding rounds Celsis was successfully floated on the London Stock Exchange in June 1993. Peter completed his tenure at Celsis as Director of Business Development and Technology leaving in 2002 to set up Fusion IP PLC.

David Baynes - Non-Executive Director

David Baynes is a Chief Executive Officer of Fusion IP PLC. David was appointed to this role in 2004, having previously been director of Fusion IP Trading since 2003. Fusion IP PLC has exclusive agreements with The University of Sheffield and Cardiff University by which it owns the right to commercialise any IP generated by those institutions. Since floatation the company has completed 3 secondary transactions on AIM and now has 24 portfolio companies and David sits on the Board of 10 of these. David has previously worked at Celsis International PLC from its incorporation to its flotation on the full list of the London Stock Exchange in July 1993. David was also co-founder of Toad PLC (now TG21 plc) and was responsible for taking the company from start-up to a full listing on the London Stock Exchange.

Jocelyn Brown, MBA - Board Member

Jocelyn Brown is a member of the Early Stage Investments Team at Finance Wales, a provider of commercial funding (debt and equity) to small and medium-sized businesses throughout Wales Previously, Jocelyn worked for Capgemini Consulting, where she was awarded the ‘Gold Wings’ Award for Innovation and the ‘Sales Star’ Award in Health and Life Sciences. Jocelyn began her career with SPSS Inc., a market leader in enterprise analytics. Later Jocelyn joined InferMed, a Tech Track 100, venture capital-funded start-up providing electronic data capture software for clinical trials. There, she managed implementation, validation, and technical consultancy projects for the pharmaceutical industry in the US and Europe. Jocelyn holds an MA in History from Newnham College, University of Cambridge and an MBA, with Distinction, from Tanaka Business School, Imperial College London where she was awarded a Graduate Assistantship (scholarship) by Imperial Innovations, the college’s Technology Transfer Office.

Diurnal has a strong, multi-skilled and entrepreneurial management team in place to deliver the company's clinical and commercial objectives.

Kevin Bryett, MB BS MFPM – Non-Executive Chairman

Kevin Bryett originally qualified as a physician at St George’s Medical School London, and worked in both hospital and general practice before entering the pharmaceutical industry in 1982. Subsequently, he has held a number of senior management positions in the global vaccines industry, including Managing Director of companies in the UK and Germany, and Vice President of European Commercial Operations for Aventis (now Sanofi) Pasteur MSD. More recently he held the position of Vice President of Global Commercial Operations for the world’s fifth largest vaccines business, Chiron Vaccines. In this role he was a core member of the team that managed the $1 billion acquisition of the world’s sixth largest vaccines company, PowderJect Pharmaceuticals. As a senior industry executive, Dr Bryett has sat on several strategic and operational Boards both globally and in a number of European countries. He now divides his time between running his own management consultancy and acting as a non-executive director in the biotechnology sector.

Martin Whitaker, PhD – General Manager

Martin Whitaker is Business Manager for Fusion IP PLC. In this role Martin identifies, develops and manages commercial projects emanating from the Faculty of Medicine at The University of Sheffield. Martin is also Director of Faveo Limited commercialising intellectual property in the apparel field. Prior to this Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital backed drug delivery company spun out of the University of Nottingham. Martin had overall responsibility for product development, building and developing the scientific team as well being part of the fund raising team that secured £3M in funding over a four year period. Martin is a biochemist by background and has a PhD in Pharmaceutical Science from the University of Nottingham. Martin also spent a year working for Pfizer in the Pharmaceutical R&D Department at Pfizer Global R&D (UK).

Richard Ross, MD FRCP – Chief Scientific Officer

Richard Ross is a founding director of the Diurnal. Richard is a clinical Endocrinologist in the Department of Human Metabolism, University of Sheffield and was previously a Senior Lecturer at St. Bartholomew's Hospital, London. Richard’s primary research interest is pituitary disease with a particular focus on hormone replacement. He has been a member of the editorial boards of four international endocrine journals, and served as an elected member of council for the Society for Endocrinology. He has extensive experience in both investigator led and pharmaceutically driven clinical trials. Richard has acted as a consultant for most of the big pharmaceutical companies active in the endocrine field including: Pharmacia, Novo Nordisk, Eli Lilly, Serono, Ferring and Ipsen and is currently a member of a Lilly International Advisory Board. Richard has published over a 100 peer-reviewed articles including recent publications in Nature Medicine, Nature Genetics, The Lancet, and PNAS.

Hiep Huatan, PhD – Development Director

Hiep Huatan is a pharmaceutical development consultant and Managing Director of H2 Pharma Consulting Limited and D3 Pharma Limited. Prior to this Hiep held the position of VP, Research and Development at Phoqus Pharmaceuticals, an AIM listed biotechnology company. Before joining Phoqus Pharmaceuticals, Hiep held a number of senior positions at Pfizer Global R&D (UK), where he was pivotally involved with the development and successful registration of Revatio^® in Europe and US, Tykosyn^® in Japan and Revolution^® in Europe. Hiep has over fifteen years of pharmaceutical and biotechnology product development experience. Hiep graduated in Pharmacy from the University of Nottingham and gained his PhD in Pharmaceutics from the University of Manchester. Hiep is a qualified pharmacist and a registered member of the Royal Pharmaceutical Society of Great Britain.

Diurnal has brought together key opinion leaders from across the world to advise on its products so that these are developed to meet the needs of patients. The Diurnal Scientific Advisory Board comprises both clinicians and industrialists who are well recognised and experienced in the field of hormone replacement.

Diurnal products are developed to provide more effective, physiological hormone replacement for patients. Diurnal actively engages with patient groups and organisations to keep patients updated and to disseminate information on Diurnal product development.